Clinical trials: HDL
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Diabetes
Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients
Statins have been shown to reduce significantly the risk for cardiovascular events in patients with type 2 diabetes and statin therapy is largely recommended in this high cardiovascular risk population.
- Trial name
- NCT00658463
- Testing
- Rosuvastatin
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Dyslipidemia
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
The primary purpose of your participation in this study is to help answer the following research question(s) Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat…
- Trial name
- NCT01105975
- Testing
- LY2484595, Atorvastatin, Simvastatin
- Where
- 59 sites in United States, Denmark and 4 more
- Volunteers
- 398 people
- Sponsor
- Eli Lilly and Company
HIV Infections
HIV Antiretroviral Drugs and Metabolism
Hypothesis 1: Ritonavir-based regimens increase triglycerides and VLDL by both increasing VLDL production and decreasing VLDL clearance.
- Trial name
- NCT00525239
- Testing
- ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Low CETP Activity, CETP Deficiency
Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
The aim of this study is to determine whether high high density lipoprotein-cholesterol(HDL-C) level and low Cholesteryl Ester Transfer Protein(CETP) activity is atherogenic or not in subjects who received health checkups.
- Conditions
- Low CETP Activity, CETP Deficiency, Hyperalphalipoproteinemia, Hyper-LDL-cholesterolemia
- Trial name
- INFINITY (NCT01916512)
- Where
- Japan
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Osaka University
Hyperlipidemias
Elevated Serum HDL in Four Generations of a Nashville Family
The purpose of this study is to determine the genetic basis of one family's hereditary hyper-HDL-emia using multiple modalities such as linkage analysis and gene array.
- Trial name
- NCT00525109
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Dyslipidemia
Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism
This study involves measuring subject's blood lipid responses after they consume a mixture of dietary fats of marine and dairy origin and vitamin supplements mixed into a milkshake, on three separate days.
- Trial name
- HDL (NCT01803594)
- Testing
- Krill Oil, Lutein, Nicotinic acid
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Davis
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diet Modification, HDL
Effects of Short-term Diet on HDL Composition and Function
The primary objective of this study is to generate preliminary data on the effects of a short-term diet of either fast food or Mediterranean type diet on HDL and microbiota composition and function in healthy subjects, which…
- Conditions
- Diet Modification, HDL, Inflammation
- Trial name
- NCT03205254
- Testing
- Mediterranean Diet, Fast food diet
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
HIV Infections, Metabolism, Lipids
An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects
1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated.
- Trial name
- NCT00144261
- Testing
- nevirapine
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Severe Sepsis, Septic Shock
The Role of Dysfunctional HDL in Severe Sepsis
Severe sepsis results in over 300,000 Emergency Department (ED) visits and 215,000 deaths annually in the US. Currently there are no effective drug therapies for sepsis.
- Conditions
- Severe Sepsis, Septic Shock, Sepsis
- Trial name
- NCT02370186
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Florida
Familial Hypoalphalipoproteinemia
CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
The purpose of this study is to assess the impact of 29 intravenous infusions of CER-001 vs. placebo, given at weekly (9 infusions) and biweekly (20 infusions) intervals on carotid vessel wall area as measured by 3TMRI, when…
- Trial name
- TANGO (NCT02697136)
- Testing
- CER-001
- Where
- 19 sites in United States, Belgium and 5 more
- Volunteers
- 30 people
- Sponsor
- Cerenis Therapeutics, SA
Cardiovascular Disease Prevention
Impact of a Nutritional Supplement on Metabolic Health
There are prevalent micronutrient and fiber deficiencies in a significant proportion of US population, particularly among the overweight or obese.
- Trial name
- CHORIBar (NCT02239198)
- Testing
- Nutrition bar
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Cardiovascular Diseases, Blood Pressure
Evaluation of a Novel Indoor Air Pollution Intervention Among Older Adults
Particulate matter air pollution is the leading environmental risk factor of cardiovascular disease and is increasing in the Western United States due to more frequent and severe wildfires.
- Conditions
- Cardiovascular Diseases, Blood Pressure, Glycated Hemoglobin (HbA1c), Cholesterol
- Trial name
- NCT07539987
- Testing
- Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE), Portable Air Cleaner (PAC) Control
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- University of Montana
Dyslipidemia
Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals
This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels.
- Trial name
- CLARISKI (NCT07515573)
- Testing
- Cardiol Forte
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- U.G.A. Nutraceuticals
Obesity, Weight Loss
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
The primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial…
- Trial name
- MODERATO (NCT00678483)
- Testing
- rimonabant (SR141716)
- Where
- 5 sites in Croatia, Finland and 3 more
- Volunteers
- 331 people
- Sponsor
- Sanofi
HDL
Oral Nutritional Supplement Effect on HDL Function
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
- Trial name
- NCT04529174
- Testing
- CardioLux™HDL
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Metabolic Syndrome
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use…
- Trial name
- NCT01889368
- Testing
- Grape Seed Extract
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Davis
Type 2 Diabetes Mellitus
Metabolic Effects of Alcohol
The hypotheses to be tested are 1) the use of alcohol in the form of wine with the evening meal will lower plasma glucose during the night and result in lower fasting plasma glucose the next morning; 2) the chronic use of alcohol…
- Trial name
- NCT00167115
- Testing
- Alcohol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bantle, John P., MD
Cardiovascular Disease, Hyperlipidemia
The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors
The investigators propose to evaluate the effects of avocado consumption (by incorporating 1 unit of fruit per day into a healthy diet) on multiple cardiovascular disease (CVD) risk factors.
- Trial name
- NCT01235832
- Testing
- Avocado Diet, Lower-Fat Diet, Moderate Fat Diet
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Penn State University